APA (7th ed.) Citation

EK, K., AT, L., TK, H., TT, N., A, N., CJ, H., . . . LE, H. (2023). Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer letters, 556, 216062. https://doi.org/10.1016/j.canlet.2023.216062

Chicago Style (17th ed.) Citation

EK, Kleczko, et al. "Novel EGFR-mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response." Cancer Letters 556 (2023): 216062. https://doi.org/10.1016/j.canlet.2023.216062.

MLA (9th ed.) Citation

EK, Kleczko, et al. "Novel EGFR-mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response." Cancer Letters, vol. 556, 2023, p. 216062, https://doi.org/10.1016/j.canlet.2023.216062.